Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05565495Phase 2Recruiting

The Effects of ECMO on the Pharmacokinetics of Hydromorphone

Role: lead

NCT05491278Phase 2Completed

Efficacy and Safety of Fospropofol Disodium Versus Propofol for Sedation in Mechanically Ventilated ICU Patients

Role: lead

NCT05870514Phase 2Unknown

Efficacy and Safety of Fospropofol Disodium Versus Propofol for Deep Sedation in Critically Ill Patients

Role: lead

NCT05555641Phase 2Unknown

Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation

Role: lead

All 4 trials loaded